Novel Therapies Committee
Mandate
The mandate of the Novel Therapies Committee is to advance research, education, and advocacy initiatives around non-factor replacement therapies in hemophilia (including bispecific antibodies, hemostatic rebalancing agents, and gene therapy). We will serve as a resource for collaborative research and educational projects initiated by AHCDC members and develop Canadian practice documents and guidelines.
In the committee
-
Dr. Linda (Haowei) Sun
Chair -
Dr. Jerome Teitel
Past Chair -
Dr. Mark Belletrutti
Member -
Dr. Roy Khalife
Member -
Dr. Adrienne Lee
Member -
Dr. Davide Matino
Member -
Dr. Jayson Stoffman
Member -
Dr. Margaret Warner
Member